ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. ( PRQR ) Shareholder/Analyst Call November 3, 2025 10:00 AM EST Company Participants Sarah Kiely - Vice President of Investor Relations & Corporate Communications Daniel de Boer - Founder, CEO & Member of Management Board Cristina Lopez Lopez - Chief Medical Officer Dennis Hom - Chief Financial Officer Gerard Platenburg - Co-Founder, Chief Scientific Officer & Member of Management Board Conference Call Participants Henkjan Verkade Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Kaey Nakae - Chardan Capital Markets, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Ananda Ghosh - H.C.
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.
